On the basis of type, the market has been segmented into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and immunomodulators. In this report, the global Cancer Immunotherapy Market has been segmented based on type, application, end user, and region. The monoclonal antibodies segment is expected to account for the largest share of the market in 2016, while the checkpoint inhibitors segment is projected to witness the highest CAGR from 2016 to 2021. The high growth in this segment is primarily attributed to the high success rate of these inhibitors.
According to research report Cancer Immunotherapy Market is expected to reach $119.39 Billion by 2021, at a CAGR of 14.0% from 2016 to 2021. Factors such as increasing incidence of cancer and rising healthcare expenditure are driving the growth of this market.
On the basis of applications, the global Cancer Immunotherapy Market is segmented into lung cancer, melanoma, prostate cancer, breast cancer, colorectal cancer, head & neck cancer, and others. The lung cancer segment is expected to grow at the highest CAGR during the forecast period. The high growth in this segment can be attributed to the increasing prevalence of this type of cancer and rising demand for advanced treatment options.
Key players in the Cancer Immunotherapy Market include Amgen (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Janssen Global Services, LLC (Belgium), Merck (U.S.), Novartis (Switzerland), and Pfizer (U.S.).
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197577894